Literature DB >> 1858973

Recurrent respiratory papillomatosis: progression to invasion and malignancy.

B Gaylis1, R E Hayden.   

Abstract

Recurrent respiratory papillomatosis is the most common benign tumor of the larynx in children. The disease often runs a protracted course necessitating multiple endolaryngeal procedures. Rarely, these papillomata become invasive and/or undergo malignant degeneration. A case report of malignant degeneration and widespread invasion in long-standing laryngeal papillomatosis and a review of the relevant literature are presented.

Entities:  

Mesh:

Year:  1991        PMID: 1858973     DOI: 10.1016/0196-0709(91)90045-h

Source DB:  PubMed          Journal:  Am J Otolaryngol        ISSN: 0196-0709            Impact factor:   1.808


  4 in total

1.  Pulmonary spread of laryngeal papillomatosis: radiological findings.

Authors:  Katsumi Abe; Yoshiaki Tanaka; Motoichiro Takahashi; Shigeru Kosuda; Katsumi Hayashi; Tetsuya Tanabe; Yoshie Iwasaki; Shinsuke Aida; Toshio Kawauchi; Masayoshi Yamamoto; Tamotsu Kita; Tatsumi Kaji
Journal:  Radiat Med       Date:  2006-05

2.  Early Glottic Squamous Cell Carcinoma in a 16-Year-Old: Case Report, Review of the Literature and Pediatric Head and Neck Radiotherapy Guidelines.

Authors:  Rajesh Balakrishnan; Qamruzzaman Chowdhury; Mohammed Astefchar Hussain; Muhammad Masudul Hassan Arup; Nizamul Haque; Fariah Sharmeen; Arunangshu Das; Bidoura Naznin
Journal:  Case Rep Oncol       Date:  2015-08-20

3.  Recurrent respiratory papillomatosis: HPV genotypes and risk of high-grade laryngeal neoplasia.

Authors:  Turid Omland; Kathrine A Lie; Harriet Akre; Lars Erik Sandlie; Peter Jebsen; Leiv Sandvik; Dag Andre Nymoen; Davit Bzhalava; Joakim Dillner; Kjell Brøndbo
Journal:  PLoS One       Date:  2014-06-11       Impact factor: 3.240

4.  HPV vaccination as preventive approach for recurrent respiratory papillomatosis - a 22-year retrospective clinical analysis.

Authors:  Paul Stefan Mauz; Fabian Axel Schäfer; Thomas Iftner; Phillipp Gonser
Journal:  BMC Infect Dis       Date:  2018-07-24       Impact factor: 3.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.